cbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products

Rhea-AI Summary

cbdMD (NYSE American: YCBD) welcomed the White House request that Congress ensure fair treatment of hemp-derived products under federal law. The Administration supports hemp reform, preservation of access to appropriate full-spectrum CBD, and a responsible federal framework or extended implementation timeline, aligning with cbdMD's focus on compliant, science-backed products.

News Market Reaction – YCBD

+6.34% 2.5x vol

6 alerts

+6.34% Session close to close

+7.2% Peak in 22 hr 36 min

$7.77M Market Cap

2.5x Rel. Volume

In the Jun 25 session, YCBD gained 6.34%, reflecting a notable positive market reaction. Argus tracked a peak move of +7.2% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.5x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +6.3% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +6.3% in the session following this news. A strong positive reaction aligns with the policy tailwind from the White House’s support for fair treatment of hemp-derived products. Past YCBD news often saw selling, so sustained gains could hinge on confidence in federal rulemaking.

Historical Context

4 past events · Latest: Jun 16 (Positive)

Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 16	Leadership appointment	Positive	-0.3%	New CMO named alongside disclosed double‑digit revenue growth across key brands.
May 14	Quarterly results update	Positive	-5.3%	Q2 net sales up year-over-year and sequentially, driven by Bluebird integration.
May 12	Earnings call notice	Neutral	-3.0%	Announcement of conference call to discuss second quarter financial results.
Apr 01	Medicare channel launch	Positive	-3.5%	Launch of clinical healthcare channel tied to CMS BEI Medicare pathway.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent YCBD news, even when operationally positive, has often been followed by share price declines.

Key Terms

hemp-derived, full-spectrum cbd, cannabinoid

3 terms

hemp-derived medical

"hemp-derived wellness companies, today welcomed the Administration's call"

Products or ingredients labeled "hemp-derived" are made from the hemp plant, a variety of cannabis that is legally defined by having very low levels of the psychoactive compound THC. For investors, that label matters because it affects what rules, taxes, and sales channels apply—similar to how a product marked "made from apples" can sell in different stores than one containing alcohol—so it influences market access, legal risk, and consumer demand.

full-spectrum cbd medical

"preserving access to appropriate full-spectrum CBD products, while preserving Congress's intent"

Full-spectrum CBD is a hemp-derived product that contains not only cannabidiol (CBD) but also other naturally occurring compounds from the plant—like small amounts of THC, minor cannabinoids, and aromatic oils—kept together rather than isolated. For investors, this matters because full-spectrum formulations are often marketed as more effective by leveraging the combined action of these compounds (think a whole spice mix versus a single herb), but they also carry higher regulatory, testing and labeling risks and can command different prices and customer loyalty than pure CBD isolates.

cannabinoid medical

"in a maturing cannabinoid categoryCHARLOTTE, N.C., June 25, 2026 -- cbdMD, Inc."

Cannabinoids are chemical compounds that interact with the body’s cell signaling system that influences mood, appetite, pain and inflammation; they occur naturally in the cannabis plant, are made by the body, or can be created synthetically. Investors watch cannabinoids because they are the active ingredients that determine a product’s medical effects, consumer demand and regulatory treatment—think of them as the “active ingredient” in a drug or the key flavor that drives sales and legal rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

As federal reclassification efforts advance and major U.S. exchanges open to compliant operators, cbdMD points to its position as an established, NYSE American–listed company in a maturing cannabinoid category

CHARLOTTE, N.C., June 25, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE American: YCBD), one of the nation's most recognized and trusted hemp-derived wellness companies, today welcomed the Administration's call urging Congress to ensure the fair treatment of hemp-derived products under federal law and requesting immediate action to revise federal hemp regulation to ensure fair treatment of hemp products under federal law.

In a letter to congressional leadership this week, the White House Office of Management and Budget identified hemp reform as a priority the Administration strongly supports. The request calls on Congress to ensure fair treatment of hemp-derived products by preserving access to appropriate full-spectrum CBD products, while preserving Congress's intent to restrict products that pose health risks. The Administration also urged Congress to adopt a responsible federal framework or, at minimum, extend the current implementation timeline so that lawmakers have time to get the policy right. The request builds on the President's earlier public statements urging lawmakers to protect access to the full-spectrum CBD products that millions of Americans rely on.

"We are encouraged to see the Administration advocating so clearly for responsible, science-backed hemp products that consumers depend on every day," said Ronan Kennedy, Chief Executive Officer of cbdMD. "cbdMD has always believed the future of this category is built on quality, transparency, and clear rules that distinguish responsible operators from bad actors. A federal framework that protects consumer access, promotes safety, and provides certainty for compliant companies is exactly what this industry and the people it serves deserve. We commend the policymakers who are working toward that outcome."

Separately, broader federal cannabis policy developments continue to draw investment, research, and institutional attention to the cannabinoid category. Notably, major U.S. exchanges have begun permitting the listing of the plan-touching operators that comply with federal, state and local medical cannabis framework. Although cannabis reclassification is distinct from the federal treatment of hemp-derived products, recent exchange-listing developments for compliant cannabis operators reflect a market that is moving toward greater legitimacy, transparency, and regulatory maturity. As an established hemp-derived wellness company with recognized brands, national distribution, and a listing on a national securities exchange, cbdMD believes it is well-positioned as the cannabinoid category moves toward greater maturity, transparency, and regulatory clarity.

"We believe cbdMD is purpose built for this next phase of the market," Kennedy added. "Our focus remains on serving our customers with trusted, efficacious products, supporting responsible regulation, and building long-term value for our shareholders as the category continues to evolve. Along the way, we will continue to evaluate the opportunities this evolving environment may present."

About cbdMD, Inc.

cbdMD, Inc. (NYSE American: YCBD) is a leading wellness company headquartered in Charlotte, North Carolina, with a portfolio of trusted hemp-derived and wellness brands, including cbdMD, Bluebird Botanicals, Paw CBD, ATRx Labs, and the Oasis line of hemp-derived THC beverages. The Company is committed to quality, science, and transparency across its product lines. For more information, visit cbdmd.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding potential changes to the federal regulatory framework for hemp-derived products; the timing or outcome of legislative, administrative, or agency action; the evolution of U.S. capital markets and securities exchange listing practices for the cannabinoid category; and the Company's competitive position and potential opportunities. These statements are based on management's current expectations and are subject to known and unknown risks and uncertainties.

Such risks include, without limitation: that Congress or the Administration may not act, may act on a different timeline, or may adopt adverse regulation or regulation different from what is currently proposed; the potential impact of the statutory changes to the federal definition of hemp scheduled to take effect November 12, 2026; the fact that the ongoing federal cannabis reclassification proceedings concern marijuana, are separate from and do not directly govern the regulation of hemp-derived products, and may not conclude on the timeline or with the outcome the Company anticipates; that securities exchange practices regarding the listing of cannabis-related companies may change or may not develop as expected; and other risks described in the Company's filings with the Securities and Exchange Commission. Actual results may differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Contacts

cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
IR@cbdmd.com
(704) 445-3064

View original content to download multimedia:https://www.prnewswire.com/news-releases/cbdmd-welcomes-white-house-call-for-fair-treatment-of-hemp-derived-products-302811088.html

SOURCE cbdMD, Inc.

FAQ

What White House action on hemp-derived products did cbdMD (YCBD) welcome on June 25, 2026?

cbdMD welcomed the Administration’s request that Congress ensure fair treatment of hemp-derived products under federal law. According to cbdMD, the White House called hemp reform a priority and urged preservation of access to appropriate full-spectrum CBD products while restricting products that pose health risks.

How could the White House hemp reform request impact cbdMD (YCBD) and its CBD products?

The White House request could support clearer, fairer federal rules for hemp-derived products. According to cbdMD, a responsible federal framework that protects consumer access and promotes safety would provide greater certainty for compliant companies and help distinguish responsible operators from bad actors in the cannabinoid market.

What federal policy changes for hemp products does the Biden Administration support, relevant to cbdMD (YCBD)?

The Administration supports revising federal hemp regulation to ensure fair treatment of hemp-derived products. According to cbdMD, the White House urged Congress to preserve access to appropriate full-spectrum CBD while restricting risky products and either adopt a responsible federal framework or extend current implementation timelines.

How does cbdMD (YCBD) describe its position in the evolving cannabinoid market?

cbdMD describes itself as an established hemp-derived wellness company with national distribution and a NYSE American listing. According to cbdMD, these factors, plus recognized brands and focus on quality and transparency, position it for a maturing, more regulated cannabinoid category in the United States.

What does cbdMD (YCBD) say about broader cannabis policy and exchange listings?

cbdMD notes that major U.S. exchanges now permit listings of certain compliant cannabis operators. According to cbdMD, these developments, alongside cannabis reclassification efforts, signal a market moving toward greater legitimacy, transparency, and regulatory maturity, which may create future opportunities the company will continue to evaluate.